Johnson & Johnson ROA 2010-2024 | JNJ
Current and historical return on assets (ROA) values for Johnson & Johnson (JNJ) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets.
| Johnson & Johnson ROA - Return on Assets Historical Data |
| Date |
TTM Net Income |
Total Assets |
Return on Assets |
| 2024-09-30 |
$14.68B |
$178.29B |
8.40% |
| 2024-06-30 |
$38.02B |
$181.09B |
22.15% |
| 2024-03-31 |
$38.48B |
$171.97B |
22.07% |
| 2023-12-31 |
$35.15B |
$167.56B |
19.49% |
| 2023-09-30 |
$34.62B |
$166.06B |
18.69% |
| 2023-06-30 |
$13.05B |
$191.69B |
6.96% |
| 2023-03-31 |
$12.72B |
$195.97B |
6.91% |
| 2022-12-31 |
$17.94B |
$187.38B |
9.99% |
| 2022-09-30 |
$19.16B |
$175.12B |
10.74% |
| 2022-06-30 |
$18.37B |
$177.72B |
10.24% |
| 2022-03-31 |
$19.83B |
$178.36B |
11.08% |
| 2021-12-31 |
$20.88B |
$182.02B |
11.76% |
| 2021-09-30 |
$17.88B |
$179.23B |
10.17% |
| 2021-06-30 |
$17.77B |
$176.44B |
10.23% |
| 2021-03-31 |
$15.12B |
$172.56B |
8.94% |
| 2020-12-31 |
$14.71B |
$174.89B |
8.93% |
| 2020-09-30 |
$16.99B |
$170.69B |
10.59% |
| 2020-06-30 |
$15.19B |
$158.38B |
9.69% |
| 2020-03-31 |
$17.17B |
$155.02B |
11.01% |
| 2019-12-31 |
$15.12B |
$157.73B |
9.78% |
| 2019-09-30 |
$14.15B |
$155.52B |
9.22% |
| 2019-06-30 |
$16.33B |
$155.12B |
10.64% |
| 2019-03-31 |
$14.68B |
$150.03B |
9.56% |
| 2018-12-31 |
$15.30B |
$152.95B |
9.86% |
| 2018-09-30 |
$1.54B |
$155.70B |
0.99% |
| 2018-06-30 |
$1.37B |
$155.37B |
0.88% |
| 2018-03-31 |
$1.25B |
$156.63B |
0.80% |
| 2017-12-31 |
$1.30B |
$157.30B |
0.85% |
| 2017-09-30 |
$15.83B |
$155.66B |
10.65% |
| 2017-06-30 |
$16.34B |
$152.81B |
11.28% |
| 2017-03-31 |
$16.51B |
$144.92B |
11.66% |
| 2016-12-31 |
$16.54B |
$141.21B |
11.86% |
| 2016-09-30 |
$15.94B |
$140.37B |
11.60% |
| 2016-06-30 |
$15.03B |
$139.81B |
11.08% |
| 2016-03-31 |
$15.55B |
$136.23B |
11.62% |
| 2015-12-31 |
$15.41B |
$133.41B |
11.69% |
| 2015-09-30 |
$14.72B |
$133.27B |
11.23% |
| 2015-06-30 |
$16.11B |
$132.04B |
12.32% |
| 2015-03-31 |
$15.92B |
$128.59B |
12.10% |
| 2014-12-31 |
$16.32B |
$130.36B |
12.30% |
| 2014-09-30 |
$17.32B |
$132.10B |
12.99% |
| 2014-06-30 |
$15.55B |
$135.20B |
11.78% |
| 2014-03-31 |
$15.06B |
$133.33B |
11.65% |
| 2013-12-31 |
$13.83B |
$132.68B |
10.94% |
| 2013-09-30 |
$12.88B |
$126.93B |
10.43% |
| 2013-06-30 |
$12.87B |
$124.33B |
10.59% |
| 2013-03-31 |
$10.44B |
$121.54B |
8.74% |
| 2012-12-31 |
$10.85B |
$121.35B |
9.19% |
| 2012-09-30 |
$8.50B |
$118.95B |
7.32% |
| 2012-06-30 |
$8.74B |
$115.75B |
7.64% |
| 2012-03-31 |
$10.11B |
$116.19B |
8.91% |
| 2011-12-31 |
$9.67B |
$113.64B |
8.68% |
| 2011-09-30 |
$11.40B |
$111.82B |
10.48% |
| 2011-06-30 |
$11.61B |
$112.11B |
11.02% |
| 2011-03-31 |
$12.28B |
$108.15B |
12.23% |
| 2010-12-31 |
$13.33B |
$102.91B |
13.79% |
| 2010-09-30 |
$13.60B |
$98.25B |
14.36% |
| 2010-06-30 |
$13.53B |
$92.30B |
14.54% |
| 2010-03-31 |
$13.29B |
$93.44B |
14.47% |
| 2009-12-31 |
$12.27B |
$94.68B |
13.64% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$368.366B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
